Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 180

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 180
---
 pending criminal proceeding (excluding traffic violations and other minor offences); |

| ● | being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; or |

| ● | being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated. |

There have been no material legal proceedings that would require disclosure under the federal securities laws that are material to an evaluation of the ability or integrity of our directors or executive officers, or in which any director, officer, nominee or principal stockholder, or any affiliate thereof, is a party adverse to us or has a material interest adverse to us. Director Independence Our Board has reviewed the materiality of any relationship that each of our Directors has with Petros, either directly or indirectly. Based upon this review, our Board has determined that the following Directors are “independent directors” as defined by The Nasdaq Stock Market (“Nasdaq”): Joshua N. Silverman
Bruce T. Bernstein
Wayne R. Walker Board Committees and Meetings During the fiscal year ended December 31, 2024, the Board held two meetings. Each director attended at least 75% of all Board and applicable committee meetings in fiscal year 2024. The Board has adopted a policy under which each member of the Board is encouraged to attend each annual meeting of our stockholders. For our 2024 Annual Meeting of Stockholders, one board member attended the meeting. Our Board has established three standing committees of the Board, each of which is composed solely of independent directors:

| ● | The Audit Committee consists of Mr. Bernstein, as Chairman, Mr. Silverman and Mr. Walker. |

| ● | The Compensation Committee consists of Mr. Silverman, as Chairman, Mr. Bernstein and Mr. Walker. |

| ● | The Nominating and Corporate Governance Committee consists of Mr. Walker, as Chairman, Mr. Bernstein and Mr. Silverman. |

105

Each of the committees has a written charter adopted by the Board; a current copy of each such charter is available in the “Investor Relations” section on our website at http://www.petrospharma.com/investors. Audit Committee Our Audit Committee